In a significant development for patients battling advanced stages of multiple sclerosis, Sanofi has announced that its investigational drug Cenrifki (tolebrutinib) has received a positive recommendation for approval in Europe. The opinion was issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), marking an important step toward making the therapy available to patients.
The recommendation specifically targets individuals suffering from secondary progressive multiple sclerosis (SPMS) without recent relapses, a stage of the disease where disability steadily worsens and treatment options are extremely limited. This condition often leads to severe mobility issues, cognitive decline, fatigue, and loss of independence, creating a major unmet medical need.
The CHMP’s decision is backed by results from the Phase 3 HERCULES study, which showed that Cenrifki significantly delayed the progression of disability in patients with non-relapsing SPMS. Additional supporting data came from the GEMINI 1 and GEMINI 2 trials, further strengthening confidence in the drug’s effectiveness.
What makes tolebrutinib particularly noteworthy is its ability to penetrate the brain and target underlying disease mechanisms, something that has been challenging for many existing therapies. If approved, it could become one of the first treatments to directly address disability progression in this patient group.
While the CHMP recommendation is a major milestone, the final decision now rests with the European Commission, which is expected to deliver its verdict in the coming months.
If cleared, Cenrifki could reshape the treatment landscape for progressive multiple sclerosis, offering new hope to thousands of patients who currently have limited therapeutic options. However, until final approval is granted, clinicians and patients alike will be watching closely as the regulatory process moves forward.
